Results 51 to 60 of about 4,418 (114)

Interaction study of CD20 and Rituximab’s scFv to propose an anti-CD20 CAR [PDF]

Annals of the V ISI, 2021
Alison Rebouças, Marcos Lourenzoni
openaire   +1 more source

CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment

Journal of Hematology & Oncology
Background Baseline CD20 expression ≥ 20% in B-cell acute lymphoblastic leukemia (B-ALL) has been associated with poorer outcomes, which improved after rituximab introduction into frontline therapy for CD20-positive cases.
Monika Szczepanowski, Johanna Richter, Sonja Bendig, Lorenz Bastian, Miriam Kelm, Veronika Beck, Thomas Beder, Guranda Chitadze, Michaela Kotrová, Johannes Duell, Christoph Faul, Johannes Gärtner, Alina Hartmann, Britta Kehden, Eva Maria Murga Penas, Martin Neumann, Matthias Ritgen, Wiebke Schrader, Björn Steffen, Heiko Trautmann, Andreas Viardot, Thomas Burmeister, Claudia D. Baldus, Stefan Schwartz, Nicola Gökbuget, Monika Brüggemann   +25 more
doaj   +1 more source

Very low doses of rituximab in autoimmune hemolytic anemia—an open-label, phase II pilot trial

Frontiers in Medicine
IntroductionAlthough rituximab is approved for several autoimmune diseases, no formal dose finding studies have been conducted. The amount of CD20+ cells differs significantly between autoimmune diseases and B-cell malignancies.
Miriam M. Moser, Renate Thalhammer, Christian Sillaber, Ulla Derhaschnig, Christa Firbas, Ulrich Jäger, Bernd Jilma, Christian Schoergenhofer   +7 more
doaj   +1 more source

A CCL5+CD20+CD8+ T cell subset drives pathogenic transformation of synoviocytes in rheumatoid arthritis via JAK-STAT signaling

Cell & Bioscience
Background In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) acquire an aggressive phenotype promoting inflammation and joint damage. While FLS interactions with recruited T cells are established, drivers of FLS aggressiveness and the role
Haonan Jia, Jiawei Xue, Suna Jiang, Wenjing Li, Xuemin Wei, Yanli Wang, Jianyang Zhuang, Xiaoying Zhu, Hongying Li, Xu Liu, Maolin Chu, Zhiyi Zhang, Juan Zhang   +12 more
doaj   +1 more source

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

Journal of Translational Medicine
Background Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy.
Na Yang, Caili Zhang, Yingchun Zhang, Yuting Fan, Jing Zhang, Xiaojin Lin, Ting Guo, Yangzuo Gu, Jieheng Wu, Jianmei Gao, Xing Zhao, Zhixu He   +11 more
doaj   +1 more source

Characterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies.

PLoS ONE
This study characterizes the previously reported anti-canine CD20 antibody 4E1-7-B_f and compares this with commercially available anti-human CD20 antibodies, rituximab and an obinutuzumab biosimilar.
Takuya Mizuno, Yukinari Kato, Toshihiro Tsukui, Masaya Igase   +3 more
doaj   +1 more source

P106 | Cd20 positive multiple myeloma: is it a different entity?

Haematologica
Introduction. Expression of CD20 antigen is generally negative in patients (pts) with multiple myeloma (MM). However, a small number of MM pts (15-20%) can show CD20 positivity on neoplastic plasma cells (PC).
Monica Poscente
doaj  

CD20; CD47 [PDF]

Science-Business eXchange, 2010
openaire   +1 more source

CD20 Positive [PDF]

, 2020
openaire   +1 more source

CD20 Negative [PDF]

, 2020
openaire   +1 more source